MONTREAL, Feb. 20, 2019 /CNW/ - AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that Health Canada has approved HUMIRA® (adalimumab) for the treatment of ...
As with other medications, Humira can interact with certain other drugs. It can also interact with some vaccines. An interaction occurs when one substance causes another substance to have a different ...
The arthritis drug Humira has been a blockbuster seller for more than two decades. Now, some copycats could end Humira's reign. The blockbuster drug Humira has been one of the world's top sellers for ...
GoodRx is joining forces with drugmaker Boehringer Ingelheim to make its Humira biosimilar adalimumab available at an affordable price. The pharmaceutical company will offer citrate-free ...
As widely expected by the pharmaceutical industry, seven pharmaceutical companies are releasing biosimilars of AbbVie's Humira. Boehringer Ingelheim's Cyltezo (adalimumab-adbm), an interchangeable ...
As longtime AbbVie CEO Rick Gonzalez drives the company through its much-dreaded year of Humira biosimilar erosion, his eventual exit is coming into view. In his 10 years at the helm, the CEO has ...
AbbVie’s megablockbuster TNF blocker Humira is about to face biosimilars next year. While new competitors will almost definitely drag down the behemoth drug’s sales, the question is, what pricing ...
This is an archived article and the information in the article may be outdated. Please look at the time stamp on the story to see when it was last updated. Patients who take the autoimmune disease ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. In 2021, Humira — the blockbuster biologic that has for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results